BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 32815034)

  • 1. Inter-observer variability of cribriform architecture and percent Gleason pattern 4 in prostate cancer: relation to clinical outcome.
    van der Slot MA; Hollemans E; den Bakker MA; Hoedemaeker R; Kliffen M; Budel LM; Goemaere NNT; van Leenders GJLH
    Virchows Arch; 2021 Feb; 478(2):249-256. PubMed ID: 32815034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Percentage Gleason pattern 4 and PI-RADS score predict upgrading in biopsy Grade Group 2 prostate cancer patients without cribriform pattern.
    van der Slot MA; Seyrek N; Kweldam CF; den Bakker MA; Busstra MB; Gan M; Klaver S; Rietbergen JBW; van Leenders GJLH
    World J Urol; 2022 Nov; 40(11):2723-2729. PubMed ID: 36190529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy.
    Kweldam CF; Kümmerlin IP; Nieboer D; Verhoef EI; Steyerberg EW; van der Kwast TH; Roobol MJ; van Leenders GJ
    Mod Pathol; 2016 Jun; 29(6):630-6. PubMed ID: 26939875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternative prostate cancer grading systems incorporating percent pattern 4/5 (IQ-Gleason) and cribriform architecture (cGrade) improve prediction of outcome after radical prostatectomy.
    Seyrek N; Hollemans E; Andrinopoulou ER; Osanto S; Pelger RCM; van der Poel HG; Bekers E; Remmers S; Schoots IG; van Leenders GJLH
    Virchows Arch; 2022 Jun; 480(6):1149-1157. PubMed ID: 35157140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cribriform architecture outperforms Gleason pattern 4 percentage and tertiary Gleason pattern 5 in predicting the outcome of Grade Group 2 prostate cancer patients.
    Seyrek N; Hollemans E; Osanto S; Pelger RCM; van der Poel HG; Bekers E; Bangma CH; Rietbergen J; Roobol MJ; Schoots IG; van Leenders GJLH
    Histopathology; 2022 Feb; 80(3):558-565. PubMed ID: 34706119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of cribriform size, percentage, and intraductal carcinoma in Gleason score 7 prostate cancer with cribriform Gleason pattern 4.
    Chen Z; Pham H; Abreu A; Amin MB; Sherrod AE; Xiao GQ; Aron M
    Hum Pathol; 2021 Dec; 118():18-29. PubMed ID: 34543668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved Prostate Cancer Biopsy Grading by Incorporation of Invasive Cribriform and Intraductal Carcinoma in the 2014 Grade Groups.
    van Leenders GJLH; Kweldam CF; Hollemans E; Kümmerlin IP; Nieboer D; Verhoef EI; Remmers S; Incrocci L; Bangma CH; van der Kwast TH; Roobol MJ
    Eur Urol; 2020 Feb; 77(2):191-198. PubMed ID: 31439369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contemporary Gleason Grading of Prostatic Carcinoma: An Update With Discussion on Practical Issues to Implement the 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma.
    Epstein JI; Amin MB; Reuter VE; Humphrey PA
    Am J Surg Pathol; 2017 Apr; 41(4):e1-e7. PubMed ID: 28177964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraductal carcinoma has a minimal impact on Grade Group assignment in prostate cancer biopsy and radical prostatectomy specimens.
    Rijstenberg LL; Hansum T; Hollemans E; Kweldam CF; Kümmerlin IP; Bangma CH; van der Kwast TH; Roobol MJ; van Leenders GJLH
    Histopathology; 2020 Nov; 77(5):742-748. PubMed ID: 32542746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cribriform architecture in radical prostatectomies predicts oncological outcome in Gleason score 8 prostate cancer patients.
    Hollemans E; Verhoef EI; Bangma CH; Rietbergen J; Osanto S; Pelger RCM; van Wezel T; van der Poel H; Bekers E; Helleman J; Roobol MJ; van Leenders GJLH
    Mod Pathol; 2021 Jan; 34(1):184-193. PubMed ID: 32686748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of intraductal carcinoma and large cribriform carcinoma architecture after prostatectomy in a contemporary cohort.
    Trudel D; Downes MR; Sykes J; Kron KJ; Trachtenberg J; van der Kwast TH
    Eur J Cancer; 2014 Jun; 50(9):1610-6. PubMed ID: 24703897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate Biopsy Specimens With Gleason 3+3=6 and Intraductal Carcinoma: Radical Prostatectomy Findings and Clinical Outcomes.
    Khani F; Epstein JI
    Am J Surg Pathol; 2015 Oct; 39(10):1383-9. PubMed ID: 26076065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneous clinicopathological features of intraductal carcinoma of the prostate: a comparison between "precursor-like" and "regular type" lesions.
    Miyai K; Divatia MK; Shen SS; Miles BJ; Ayala AG; Ro JY
    Int J Clin Exp Pathol; 2014; 7(5):2518-26. PubMed ID: 24966964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Automated deep-learning system for Gleason grading of prostate cancer using biopsies: a diagnostic study.
    Bulten W; Pinckaers H; van Boven H; Vink R; de Bel T; van Ginneken B; van der Laak J; Hulsbergen-van de Kaa C; Litjens G
    Lancet Oncol; 2020 Feb; 21(2):233-241. PubMed ID: 31926805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interobserver reproducibility of percent Gleason grade 4/5 in total prostatectomy specimens.
    Glaessgen A; Hamberg H; Pihl CG; Sundelin B; Nilsson B; Egevad L
    J Urol; 2002 Nov; 168(5):2006-10. PubMed ID: 12394696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer.
    Epstein JI; Amin MB; Fine SW; Algaba F; Aron M; Baydar DE; Beltran AL; Brimo F; Cheville JC; Colecchia M; Comperat E; da Cunha IW; Delprado W; DeMarzo AM; Giannico GA; Gordetsky JB; Guo CC; Hansel DE; Hirsch MS; Huang J; Humphrey PA; Jimenez RE; Khani F; Kong Q; Kryvenko ON; Kunju LP; Lal P; Latour M; Lotan T; Maclean F; Magi-Galluzzi C; Mehra R; Menon S; Miyamoto H; Montironi R; Netto GJ; Nguyen JK; Osunkoya AO; Parwani A; Robinson BD; Rubin MA; Shah RB; So JS; Takahashi H; Tavora F; Tretiakova MS; True L; Wobker SE; Yang XJ; Zhou M; Zynger DL; Trpkov K
    Arch Pathol Lab Med; 2021 Apr; 145(4):461-493. PubMed ID: 32589068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological analysis of intraductal proliferative lesions of prostate: intraductal carcinoma of prostate, high-grade prostatic intraepithelial neoplasia, and atypical cribriform lesion.
    Miyai K; Divatia MK; Shen SS; Miles BJ; Ayala AG; Ro JY
    Hum Pathol; 2014 Aug; 45(8):1572-81. PubMed ID: 24842280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [SIGNIFICANCE OF INTRADUCTAL CARCINOMA OF THE PROSTATE IN POST-OPERATIVE BIOCHEMICAL RECURRENCE].
    Sakamoto N; Ueda S; Mizoguchi H; Kawahara I; Kobayashi T; Hamaguchi M; Yoshikawa M
    Nihon Hinyokika Gakkai Zasshi; 2017; 108(1):5-11. PubMed ID: 29367511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Large cribriform growth pattern identifies ISUP grade 2 prostate cancer at high risk for recurrence and metastasis.
    Hollemans E; Verhoef EI; Bangma CH; Rietbergen J; Helleman J; Roobol MJ; van Leenders GJLH
    Mod Pathol; 2019 Jan; 32(1):139-146. PubMed ID: 30349027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Significance of Percentage and Architectural Types of Contemporary Gleason Pattern 4 Prostate Cancer in Radical Prostatectomy.
    Choy B; Pearce SM; Anderson BB; Shalhav AL; Zagaja G; Eggener SE; Paner GP
    Am J Surg Pathol; 2016 Oct; 40(10):1400-6. PubMed ID: 27379821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.